Invesco Floating Rate Municipal Income ETF·Financial Services
The Invesco Floating Rate Municipal Income ETF (Fund) is based on the ICE US Municipal AMT-Free VRDO Constrained Index (Index). The Fund generally will invest at least 80% of its total assets in U.S. dollar tax-exempt variable rate demand obligations (VRDOs). The Index tracks the performance of U.S. dollar tax-exempt VRDOs that are publicly issued by U.S. states and territories, and their political subdivisions, and that have interest rates that reset daily, weekly or monthly. The Fund does not purchase all of the securities in the Index; instead, the Fund utilizes a "sampling" methodology to seek to achieve its investment objective. The Fund and the Index are rebalanced on the last calendar day of the month.Effective after the close of markets on Aug. 25, 2023, the Fund’s name will change from Invesco VRDO Tax-Free ETF to Invesco Floating Rate Municipal Income ETF. No other changes were made to the Fund. See the prospectus for more information.
Financial Services
Asset Management
2007-11-15
-0.01
Market Peers







Being Published in the Journal of Vascular and Interventional Radiology, a Premier Peer-Reviewed Journal, Speaks to the Quality and Impact of the Study Company Remains Focused on Expanding Evidence-Based Data to Support Broader Commercial Adoption of the LIBERTY System HINGHAM, Mass., March 24, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, which is already garnering medical and industry attention, today announced the publication of an article in the Journal of Vascular and Interventional Radiology (JVIR), titled “In Vivo Evaluation of a Disposable Endovascular Robotic System for Arterial Peripheral Vascular Interventions: A Multicenter Feasibility Study.

BOSTON--(BUSINESS WIRE)-- #AFSymposium2026--Vektor Medical, a medical technology company transforming cardiac arrhythmia care, today announced its participation in AF Symposium 2026, taking place February 5–8 in Boston, where new clinical data and physician experiences will highlight how vMap can help improve procedural efficiency, enhance arrhythmia termination, and help enable post-ablation non-inducibility. At this year's meeting, a featured study titled “High Procedural Efficiency and Arrhythmia Non-Inducibil.